Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
08. Juni 2023 08:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with...
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
07. Juni 2023 09:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that several operational improvement initiatives which commenced at...
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
22. Mai 2023 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a...
Precipio Shares Growth Catalysts For HemeScreen
17. Mai 2023 16:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that...
Precipio Announces Q1-2023 Shareholder Update Call
15. Mai 2023 16:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET....
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
04. Mai 2023 13:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize...
Precipio Signs Another HemeScreen™ Customer
04. Mai 2023 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology...
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
27. April 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces notification by the NASDAQ Stock Market that the Company has been...
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
19. April 2023 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 19, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q1-2023 product revenues have surpassed product revenues...
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
28. März 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday,...